Low MicroRNA-126 Levels in Right Ventricular Endomyocardial Biopsies Coincide With Cardiac Allograft Vasculopathy in Heart Transplant Patients.
Journal
Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
09
2019
revised:
02
02
2020
accepted:
02
03
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Endothelium-enriched microRNAs (miRs) are involved in the development of cardiac allograft vasculopathy (CAV). Recently, serum-derived miR-126-3p and -5p, known endothelial microRNAs with a crucial function in angiogenesis and re-endothelialization, provided additional predictive power for cardiac allograft vasculopathy in addition to clinical predictors. However, their myocardial expression in and relationship with CAV are still unknown. Our study aim was to investigate the expression of endomyocardial microRNA-126-3p and microRNA-126-5p levels in heart transplant recipients and their relationship with allograft vasculopathy. We studied 39 heart transplant recipients, 21 with proven allograft vasculopathy (CAV+) and 18 without allograft vasculopathy (CAV-) with serial coronary angiograms. Additionally, 8 patients with end-stage native coronary artery disease (CAD) were added to the study to investigate disease specificity of the microRNA signature. The mRNA levels of miR-126-3p and miR-126-5p were determined by qRT-PCR in the right ventricular endomyocardial biopsies obtained at baseline and during routine follow-up. MiR-126-3p levels were significantly lower in the CAV+ group compared to the CAV- group at follow-up, while miR-126-5p levels were unaltered. This was in stark contrast to native CAD patients in whom miR-126-3p and -5p levels were significantly higher. qPCR levels of miR-126 targets are differentially regulated in CAV versus ischemic cardiomyopathy and are influenced by the administration of immunosuppressive agents in endothelial cells. Our data provide evidence for a distinct microRNA signature in heart transplantation patients with allograft vasculopathy. In contrast to CAD patients, lower miR-126-3p levels coincide with the development of cardiac allograft vasculopathy. Further studies in a larger patient population are warranted to determine if the serial measurement of myocardial microRNA-126 products could help in risk assessment and early detection of CAV.
Identifiants
pubmed: 32548243
doi: 10.1097/TXD.0000000000000995
pmc: PMC7213604
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e549Informations de copyright
Copyright © 2020 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Nat Med. 2014 Apr;20(4):368-76
pubmed: 24584117
Arterioscler Thromb Vasc Biol. 2015 Nov;35(11):2401-11
pubmed: 26381870
Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):449-54
pubmed: 23324496
Atherosclerosis. 2011 Nov;219(1):211-7
pubmed: 21820659
Eur Heart J. 2016 Jun 07;37(22):1738-49
pubmed: 26916800
J Am Coll Cardiol. 2016 Jul 26;68(4):382-92
pubmed: 27443435
Circ Cardiovasc Imaging. 2015 Jan;8(1):
pubmed: 25596140
Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1050-9
pubmed: 23396454
J Heart Lung Transplant. 2015 Nov;34(11):1376-84
pubmed: 26198441
Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2383-90
pubmed: 22011751
Curr Vasc Pharmacol. 2012 Mar;10(2):206-15
pubmed: 22239627
Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):e15-6
pubmed: 24833799
Clin Chem. 2013 Dec;59(12):1708-21
pubmed: 23729638
Circulation. 2011 Nov 1;124(18):1936-44
pubmed: 21969012
J Am Coll Cardiol. 2016 Jul 5;68(1):80-91
pubmed: 27364054
Transplantation. 2017 Jan;101(1):e26-e33
pubmed: 27653298